Last reviewed · How we verify
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
Details
| Lead sponsor | Zai Lab (Shanghai) Co., Ltd. |
|---|---|
| Phase | PHASE3 |
| Status | RECRUITING |
| Enrolment | 99 |
| Start date | Fri Dec 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Jan 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Thyroid Eye Disease (TED)
Interventions
- ZL-1109 (VRDN-003)
- Placebo
Countries
China